<DOC>
	<DOC>NCT02405065</DOC>
	<brief_summary>The main objective of this study is to determine the maximum tolerated dose (MTD) and recommended phase 2 dose of HM95573.</brief_summary>
	<brief_title>Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573</brief_title>
	<detailed_description>Besides the main objective, there are 3 other objectives as follows: - To evaluate the anti-cancer effect of HM95573 in solid tumor patients - To investigate the pharmacokinetic profile of HM95573 after oral administration. - To investigate biomarkers related to the safety and efficacy of HM95573.</detailed_description>
	<criteria>Patients must be 20 years of age or older Subjects who have provided voluntary consent to participate in the study, and signed the written consent document. Estimated life expectancy of at least 12 weeks Histologically or cytologically confirmed advanced solid tumor Symptomatic or uncontrolled central nervous system metastases Patients who are unable to take tablets orally or have a clinically significant gastrointestinal disorder, which may interfere with administration, metabolism and absorption of the investigational drug. Patients who, in the investigator's opinion, are not suitable for the study for any other reason.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>